Cadila Healthcare Limited, a Rs. 9,200 crore global pharmaceuticals company, and its subsidiary Zydus Pharmaceuticals (USA) Inc., a leading generic pharmaceutical company in the United States, announced that the patent litigation relating to Aptalis’s Canasa (mesalamine suppository, 1 g) has been settled.
As a result of the settlement, its US subsidiary, Zydus Pharmaceuticals (USA) Inc., will be able to market its generic version of Canasa in the United States beginning on June 13, 2019, or earlier under certain circumstances.
Zydus Cadila previously received tentative approval from the US FDA to market its generic version of Canasa (mesalamine suppository, 1 g). Canasa is indicated to treat mildly to moderately active ulcerative colitis. Zydus Cadila’s generic product will be produced at the group’s topical plant at Ahmedabad.